Pay in 4 interest-free payments of $5.37 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
A synthetic 39-amino-acid triple receptor agonist (GLP-1R, GIPR, GCGR) also known as LY3437943
Glucagon-like peptide 1/glucagon receptor dual agonism reverses obesity in mice
We will also share a semaglutide weight loss dosage chart that breaks this all down at a quick glance, so you can easily reference the dosing schedule
Progressive overload principles, applied consistently over time, produce measurable improvements in body composition without the risks associated with pharmacological manipulation
**Conclusion:** Based on the current lack of safety data, Tirzepatide (Zepbound) is **generally not recommended for weight loss while breastfeeding.** If you are postpartum and *not* breastfeeding, using Zepbound is a possibility *only if* you meet the standard FDA eligibility criteria and have adequately recovered from childbirth
Users should never exceed recommended dosages, as doing so can lead to an increased likelihood of side effects and complications
